Dirk Dembski, former VP of Sales & Marketing at Olympus Biotech, is the new CEO at Frankfurt, Germany-based curasan AG. The company provides products which help physicians improve bone healing, osteoarthritis therapy and hemostasis in the dental and orthopedics fields.
Dirk Dembski: New CEO at curasan AG
1 min read Premium comments
#osteoarthritisSecondary#curasanag#dirkdembski#regenerativebonehealing
Dirk Dembski told OTW, “The vision and purpose of curasan is to broaden the horizons of musculoskeletal and dental regenerative medicine. As this is more and more a question of biologics and biotechnology, we are now bringing more exceptional talents on board and also intensify R&D collaborations with partners in Europe, North America, Japan and China. On the commercial side we are joining forces with strategic partners.”
Dembski brings many years of experience in biotechnology and the medical device sector, including positions as Managing Director at Chinese Naton Medical Group, and as a member of the Supervisory Board at Bone Therapeutics SA.
“The products of curasan AG have been known and appreciated for decades by medical professionals around the globe for their quality and effectiveness,” stated Dembski. “When it comes to regeneration of musculoskeletal and dental defects as well as pain management, we are among the first points of contact.”
“Our next step will be to fill gaps in our portfolio in the short term with complementary, disruptive and innovative products. At the same time, we are working on solutions to revolutionize musculoskeletal healing. Our stated goal is to help the body to heal itself instead of making medical repairs as is common today. Meanwhile, we are also enlarging our international footprint and invest in our brand awareness with a dedicated marketing and sales approach at all touchpoints with all stakeholders.”
Alexander Baratta, previously interim CEO and future Chairman of the Supervisory Board adds: “We are delighted to have been able to attract Dirk Dembski to our company. He brings both, the personal and professional qualifications to successfully drive curasan’s growth.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.